CSM Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$744K Sell
3,209
-1,359
-30% -$336K 0.02% 349
2026
Q2
$1.1M Sell
4,568
-401
-8% -$87.8K 0.02% 338
2026
Q1
$939K Buy
4,969
+306
+7% +$53.5K 0.02% 338
2025
Q4
$793K Sell
4,663
-1,383
-23% -$212K 0.02% 340
2025
Q3
$796K Buy
6,046
+947
+19% +$114K 0.02% 346
2025
Q2
$541K Buy
+5,099
New +$554K 0.02% 333

Other funds holding JAZZ

CSM Advisors's JAZZ Position: Q3 2026 in Review

CSM Advisors reduced its Jazz Pharmaceuticals (JAZZ) stake by 30% in Q3 2026, selling an estimated $336K and leaving 3,209 shares worth $744K. The position accounts for 0.02% of the portfolio, ranked #349.

CSM Advisors first reported a position in JAZZ in Q2 2025 and has held it in 6 quarters since. The position peaked at $1.1M in Q2 2026. 672 funds tracked by Wall St. Rank hold JAZZ as of Q3 2026.

  • CSM Advisors held 3,209 shares of Jazz Pharmaceuticals worth $744K as of Q3 2026.
  • CSM Advisors sold 1,359 Jazz Pharmaceuticals shares in Q3 2026, an estimated $336K.
  • Jazz Pharmaceuticals made up 0.02% of CSM Advisors's portfolio in Q3 2026, its #349 holding.
  • CSM Advisors first reported a position in Jazz Pharmaceuticals in Q2 2025 and has held it in 6 quarters since.
  • CSM Advisors's Jazz Pharmaceuticals position peaked at $1.1M in Q2 2026.
  • 672 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2026.

Based on CSM Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.